transplantation versus novel therapies in high-risk chronic lymphoblastic leukemia (cll)?
Published 7 years ago • 251 plays • Length 2:36Download video MP4
Download video MP3
Similar videos
-
3:00
how do novel agents affect allogeneic transplantation in cll?
-
1:04
defining high-risk cll: known and emerging mutations
-
0:51
novel therapies in the future of cll treatment
-
2:00
associated toxicities of novel therapies for cll
-
1:56
choosing between continuous and time-limited therapy in patients with high-risk cll
-
4:20
stories of transformation - marianne
-
4:05
comparing continuous and fixed duration therapy in cll
-
4:40
chronic lymphocytic leukemia (cll) | "my immune system killed my cancer." -doug
-
3:56
autoimmune cytopenias in cll and the impact of targeted therapies
-
1:49
treating cll in the r/r setting: switching drug classes and investigational therapies
-
2:24
what is the role of allogeneic stem cell transplantation in cll in the light of novel drugs?
-
1:50
targeted therapy in cll in 2022 and in the future
-
1:34
the mutational profile in patients with cll treated with acalabrutinib or ibrutinib
-
2:01
novel combination therapies for the treatment of cll
-
2:41
fixed-duration vs continuous therapy in cll
-
1:26
prognostic and predictive biomarkers in cll and their potential in guiding treatment decisions
-
1:39
novel cll therapies: the future
-
6:54
biomarker-guided treatment of cll in the chemo-free era
-
2:36
choosing treatment options for cll and combining novel drugs
-
2:36
treatment approaches to cll with high-risk molecular features
-
1:28
the role of allogeneic transplantation in patients with aml in the frontline setting
-
1:42
the role of allo transplantation in cll